← ANALYST RATINGS · TIPRANKS
Fulcrum Therapeutics (FULC): analyst forecast and price target
Analyst consensus
Hold0 Buy1 Hold0 Sell
Ratings of 1 analysts in the last 3 months · top analysts only12-month forecast
Based on 1 price targets given in the last 3 months, the average target is —, the highest —, the lowest —. The average is — from the last price of $3.65.
Analyst ratings 10
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.50 → $4.00+14.3% | Hold | +9.6% | Reiterated | 07.09.26on TipRanks 02:10 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.50 → $4.00+14.3% | Hold | +9.6% | Reiterated | 07.09.26on TipRanks 02:10 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.00 | Hold | +9.6% | Reiterated | 07.09.26on TipRanks 02:10 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.50 | Hold | −4.1% | Reiterated | 07.09.26on TipRanks 02:10 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.00 | Hold | +9.6% | Reiterated | 07.09.26on TipRanks 02:10 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $4.00 | Hold | +9.6% | Reiterated | 07.09.26on TipRanks 02:10 | — | |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | — | Hold | — | Reiterated | 18.08.26on TipRanks 08:25 | +1.5%next day +0.8% · 5 days −0.1% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $3.00 | Sell | −17.8% | Reiterated | 07.08.26on TipRanks 06:50 | +2.6%next day −3.6% · 5 days −4.3% | ↗ |
| Luca Issi★★★★★★★★★★#11187 · hits 39% · avg −2.1% | RBC Capital | $10.00 → $4.00−60.0% | Hold | +9.6% | Reiterated | 02.06.26on TipRanks Jun 3 21:45 | −51.2%next day +3.2% · 5 days +15.1% | ↗ |
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | — | Sell | — | Downgrade | 02.06.26on TipRanks 16:35 | +3.2%next day +4.3% · 5 days +12.8% | ↗ |
| Andrew Fein★★★★★★★★★★#267 · hits 52% · avg +23.7% | H.C. Wainwright | $25.00 → $3.00−88.0% | Hold | −17.8% | Downgrade | 02.06.26on TipRanks 06:30 | −51.2%next day +3.2% · 5 days +15.1% | ↗ |
| Joseph Schwartz★★★★★★★★★★#135 · hits 54% · avg +31.9% | Leerink Partners | $24.00 → $4.00−83.3% | Hold | +9.6% | Downgrade | 02.06.26on TipRanks 06:13 | −51.2%next day +3.2% · 5 days +15.1% | ↗ |
| Edward Tenthoff★★★★★★★★★★#3650 · hits 41% · avg +3.5% | Piper Sandler | $23.00 → $3.00−87.0% | Sell | −17.8% | Downgrade | 02.06.26on TipRanks 01:40 | −51.2%next day +3.2% · 5 days +15.1% | ↗ |
| Kristen Kluska★★★★★★★★★★#457 · hits 48% · avg +23.3% | Cantor Fitzgerald | $24.00 | Buy | +557.5% | Reiterated | 19.03.26on TipRanks Mar 20 08:15 | +2.0%next day −2.4% · 5 days +0.5% | ↗ |
| Unknown Analyst | Roth MKM | $15.00 | Buy | +311.0% | Reiterated | 08.12.25on TipRanks 09:55 | +46.3%next day +12.5% · 5 days −0.1% | ↗ |
| Matthew Biegler★★★★★★★★★★#3953 · hits 39% · avg +3.4% | Oppenheimer | $15.00 | Buy | +311.0% | Reiterated | 08.12.25on TipRanks 08:30 | +46.3%next day +12.5% · 5 days −0.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Fulcrum Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $3.00 at a price of $3.70 (−18.9%); now: $3.00 at $3.65 (−17.8%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 4 | 1 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 4 | 5 | 6 | 2 | 1 |
| Sell | 0 | 2 | 2 | 2 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.07 (from $-0.13 to $-0.01). Last quarter: $-0.34.
Best top-analyst consensus in the sector · Healthcare
About Fulcrum Therapeutics
- CEO: Alexander C. Sapir
- Employees: 9
- 26 Landsdowne Street, Cambridge, MA, 02139, US
- www.fulcrumtx.com
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
Data from the stock’s TipRanks forecast page, read 176 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗